Skip to Main Content
Our COVID-19 ResponseLearn More

Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths

Osaka, Japan – August 17, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 4 generic drugs with 13 strengths. The 2 compounds marked with an asterisk below are approved for the first time as generics.

The list of approved products:

1. Pregabalin OD Tablets, Capsules

Generic name:

Pregabalin*

Strengths:

OD Tablets, Capsules: 25mg, 75mg, 150mg

Brand products:

Lyrica® OD Tablets 25mg, 75mg, 150mg,

Lyrica® Capsules 25mg, 75mg, 150mg

2. Rivastigmine Tapes

Generic name:

Rivastigmine*

Strengths:

4.5mg, 9mg, 13.5mg, 18mg

Brand products:

EXELON® PATCH 4.5mg, 9mg, 13.5mg, 18mg,

RIVASTACH® Patches 4.5mg, 9mg, 13.5mg, 18mg

3. Bortezomib for Injection

Generic name:

Bortezomib

Strengths:

3mg

Brand products:

VELCADE® Injection 3mg

4. Famotidine Intravenous Injection

Generic name:

Famotidine

Strengths:

10mg, 20mg

Brand products:

Gaster® Injection 10mg, 20mg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.